OWL - BridgeBio Pharma inks royalty deal for lead drug
2024-01-18 07:50:08 ET
More on BridgeBio Pharma
- BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
- BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner
- BridgeBio Pharma: Taking Some Profits
- BridgeBio Phase 3 data for ATTR-CM drug published in NEJM
- BridgeBio submits FDA market application for ATTR-CM drug
For further details see:
BridgeBio Pharma inks royalty deal for lead drug